Phase II Trial Evaluating the Efficacy of 177Lutetium-PSMA-617 Treatment in Patients With Metastatic Clear Cell Renal Carcinoma Cell With Progressive Disease on First-line or Second-line Systemic Treatment

Background This study is for adults with advanced kidney cancer that has spread to other parts of the body and has continued to progress despite treatment with immunotherapy and targeted therapy. Unfortunately, treatment options at this stage of the disease are limited. The existing treatments' ability to work against cancer has not been fully looked into.
Rationale The goal of this study is to examine if a new drug treatment called 177Lutetium-PSMA-617, hereafter referred as 177Lu-PSMA-617, which holds the active ingredient 177Lutetium-PSMA and has been used as a standard treatment for advanced prostate cancer since December 2022, can also help treat advanced kidney cancer.
The drug 177Lu-PSMA-617 is being tested as an experimental treatment that targets a specific protein on cancer cells. This protein, known as prostate-specific membrane antigen (PSMA), is present on the surface of kidney cancer cells. Therefore, before the treatment begins, participants will undergo a PET (positron-emission tomography) scan to check if their kidney cancer cells express high levels of PSMA. This scan uses a small amount of radioactive material (in the form of 177Lutetium) to visualize the presence of PSMA on the cancer cells. Only participants who test positive for PSMA can take part in the study. In this approach, PSMA serves two purposes. First, it helps assess whether the cancer expresses this protein and allows 177Lu-PSMA-617 to specifically target and attach to the cancer cells. Second, 177Lu-PSMA-617 delivers a small amount of radiation directly to the tumour, which helps kill cancer cells while minimizing damage to normal cells. This type of treatment is known as a radiopharmaceutical.
Objective The primary aims are to find out if 177Lu-PSMA-617 is useful against kidney cancer and to assess its safety. Throughout the study, participants will undergo several imaging assessments to check their disease and response to treatment.
The study also includes the collection of tissue samples. Together with the information collected from the imaging assessments, this will allow further research into markers that may lead to earlier detection of tumour spread or help identify individuals who may benefit more from treatment with 177Lu-PSMA-617.
Treatment All participants will receive 177Lu-PSMA-617 through an intravenous injection at a standard dose of 7,400 MBq (megabecquerel: a measure of radioactivity). Treatments will be administered approximately every six weeks, for a maximum of six times.
Blood tests are done before and during treatment to check the participant's health and to detect any early side effects from the treatment. Different types of scans are performed before, during, and after 177Lu-PSMA-617 administration to check how well the treatment is working. After treatment ends, follow-up visits will be scheduled every six weeks during the first year. In the second year, your doctor will decide how often you need to come in for visits. These appointments are important for monitoring how the body continues to respond to the treatment. The entire study period will last approximately two years from the time of study entry.
Participants
The study will include approximately 56 participants who will be tested for PSMA expression, to obtain a minimum of 48 participants expressing PSMA entering the study. To qualify, participants must:
* Be diagnosed with advanced kidney cancer previously treated with immunotherapy and targeted therapy.
* Test positive for PSMA on a PET scan.
* Be generally healthy and able to perform daily activities.
* Be at least 18 years of age.
Benefit-risk analysis The drug 177Lu-PSMA-617 has proven to work well in treating advanced prostate cancer and could be a promising new treatment possibility for kidney cancer, although this has not yet been shown. By joining this study, participants will contribute to valuable research to better understand kidney cancer and improve treatment options for future patients. Participating in this study offers a chance to try a new treatment, which might help people with advanced kidney cancer live longer and prevent the disease from getting worse, especially for those who have limited treatment options left after immunotherapy and targeted therapy.
With all new treatments, there are possible risks and side effects associated with them. Side effects of the drug 177Lu-PSMA-617 may include feeling tired, nausea, dry mouth, loss of appetite, and changes in blood cells. While not all side effects are known yet, the study team will carefully follow participants for any side effects during and after treatment. It is important to understand that while the study is being done to provide new information, there are still some questions on the treatment's safety and how well it will work.

Start Date30 Oct 2025

Sponsor / Collaborator-

NCT06894511

/ Not yet recruitingPhase 2

A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment of Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC)

The purpose of this study is to assess whether the combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI improves radiographic progression-free survival (rPFS) or time to death compared to AAA617 alone in PSMA-positive mCRPC patients who were previously treated and progressed on ARPI in the biochemical recurrence (BCR)-non metastatic hormone sensitive prostate cancer (mHSPC), mHSPC, or non-metastatic Castration Resistant Prostate Cancer (nmCRPC) setting and have not previously received a taxane-containing regimen in the castrate resistant prostate cancer (CRPC) setting.

Start Date22 Aug 2025

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

NCT06514521

/ Not yet recruitingNot Applicable

A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting

Post marketing study on Pluvicto in Korea

Start Date29 May 2025

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

100 Clinical Results associated with Lutetium (177 Lu) Vipivotide Tetraxetan

100 Translational Medicine associated with Lutetium (177 Lu) Vipivotide Tetraxetan

100 Patents (Medical) associated with Lutetium (177 Lu) Vipivotide Tetraxetan

544

Literatures (Medical) associated with Lutetium (177 Lu) Vipivotide Tetraxetan

01 Apr 2025·Clinical Genitourinary Cancer

Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases

Article

Author: Rami, Avina ; Jacene, Heather ; Stoltenberg, Hailey ; Lang, Min ; Ravi, Praful ; Wolanski, Andrew ; Rashid, Narmeen S ; Ritzer, Jolivette

01 Apr 2025·CLINICAL NUCLEAR MEDICINE

225Ac-PSMA-617 Augmentation After Insufficient Response Under 177Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)

Article

Author: Nagel, Lea Sophie ; Schaefer-Schuler, Andrea ; Speicher, Tilman ; Khreish, Fadi ; Bartholomä, Mark ; Ezziddin, Samer ; Rosar, Florian ; Blickle, Arne ; Maus, Stephan ; Burgard, Caroline ; Bastian, Moritz B. ; Petto, Sven

Background:

Even though the introduction of 177Lu-PSMA-617 RLT represents a major milestone in the treatment of mCRPC, there are still patients who do not respond adequately to this therapy and for whom there are only limited options left. Augmenting 177Lu-PSMA-617 RLT with the alpha-emitter 225Ac-PSMA-617 may present an escalating treatment option to increase efficacy. In this study, we aim to evaluate outcome and safety of 225Ac-PSMA-617 augmentation to 177Lu-PSMA-617 RLT in patients who present insufficient response to monotherapy with 177Lu-PSMA-617 RLT.

Patients and Methods:

The study included n = 51 mCRPC patients enrolled in a prospective registry receiving 177Lu-PSMA-617 monotherapy and showing insufficient response, followed by initiation of 225Ac-PSMA-617 augmentation, with adjusted activities depending on individual patient characteristics. Biochemical response, progression-free survival, and overall survival were assessed. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0).

Results:

After initiation of 225Ac-PSMA-617 augmentation to 177Lu-PSMA-617 RLT, 24/51 patients (47.1%) exhibited partial remission, 16/51 (31.4%) stable disease, and 11/51 (21.6%) progressive disease. The median progression-free survival and overall survival rates were 6.3 months and 9.1 months, respectively. The majority of CTCAE gradings remained stable after initiating augmentation. Severe adverse events were rare, and no treatment termination due to side effects was recorded.

Conclusions:

225Ac-PSMA-617 augmented 177Lu-PSMA-617 radioligand therapy seems to be an effective escalating treatment option in patients after failure of conventional 177Lu-PSMA-617 RLT and represents a promising approach balancing antitumor effect and tolerable side effects.

01 Apr 2025·JOURNAL OF NUCLEAR MEDICINE

Therapy-Related Myeloid Neoplasms After [¹⁷⁷Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series

Article

Author: Tran, Ben ; Hofman, Michael S ; Buteau, James P ; Sutherland, Duncan E K ; Ravi Kumar, Aravind S ; Au, Lewis ; Kostos, Louise ; Kong, Grace ; Sandhu, Shahneen ; Emmett, Louise ; Wyatt, Alexander W ; Azad, Arun A ; Eifer, Michal ; Goncalves, Isaac ; Kwan, Edmond M ; Medhurst, Elizabeth

[¹⁷⁷Lu]Lu-prostate-specific membrane antigen (PSMA) therapy has a favorable toxicity profile in patients with metastatic castration-resistant prostate cancer (mCRPC). Therapy-related myeloid neoplasm (t-MN) has been described after [¹⁷⁷Lu]Lu-DOTATATE but has not, to our knowledge, yet been reported after [¹⁷⁷Lu]Lu-PSMA. This case series describes 5 patients with mCRPC who developed t-MN after [¹⁷⁷Lu]Lu-PSMA at our institution. Methods: In this single-center retrospective analysis, we reviewed all patients with mCRPC treated with [¹⁷⁷Lu]Lu-PSMA. Patients who developed biopsy-proven t-MN during or after [¹⁷⁷Lu]Lu-PSMA treatments are summarized with descriptive statistics. Results: From August 26, 2015, to December 31, 2022, 5 of 381 (1.3%) patients treated with [¹⁷⁷Lu]Lu-PSMA were subsequently diagnosed with t-MN. Their median age at cycle 1 (C1) was 78 y (range, 65-80 y). The median time from C1 to t-MN diagnosis was 33.6 mo (range, 6.0-58.8 mo). Previous treatments included docetaxel (n = 5), external-beam radiotherapy to metastases (n = 5), abiraterone (n = 4), enzalutamide (n = 3), and cabazitaxel (n = 3). On PSMA PET/CT, 4 (80%) patients had predominantly bone metastases and 1 (20%) had predominantly nodal metastases. They were treated with [¹⁷⁷Lu]Lu-PSMA-617 (n = 3) or [¹⁷⁷Lu]Lu-PSMA-I&T (n = 2). A median of 7 cycles (range, 4-12 cycles) of [¹⁷⁷Lu]Lu-PSMA was administered, with a median total cumulative activity of 49.2 GBq (range, 31.3-79.0 GBq). Prostate-specific antigen reduction of at least 50% or at least 80% from baseline was seen in 5 (100%) and 4 (80%), respectively. All had prostate-specific antigen progression preceding t-MN diagnosis. t-MN diagnosis included myelodysplastic syndrome with single-lineage dysplasia (n = 2), myelodysplastic syndrome with excess blasts 1 (n = 1), acute promyelocytic leukemia (n = 1), and acute myeloid leukemia (n = 1). At t-MN diagnosis, all patients presented with at least grade 2 cytopenia, involving one or more blood cell lines. Marrow genetic analysis revealed unfavorable karyotypes or mutations in all patients. Most patients received supportive care after t-MN diagnosis. Survival was 8.1, 31.3, 43.0, 56.0, and 60.4 mo from C1 and 1.8, 2.1, 6.8, 10.3, and 12.4 mo from t-MN diagnosis. Conclusion: In the mCRPC population after chemotherapy, we describe a low incidence of t-MN after [¹⁷⁷Lu]Lu-PSMA therapy. Ongoing follow-up is necessary to further define the true incidence of t-MN or other unexpected delayed toxicities, particularly with earlier use of [¹⁷⁷Lu]Lu-PSMA in the disease course.

350

News (Medical) associated with Lutetium (177 Lu) Vipivotide Tetraxetan

10 Apr 2025

·www.biopharmadive.com

Amid tariff turmoil, Novartis commits to spending $23B on U.S. manufacturing

Dive Brief:Novartis will substantially expand its U.S. footprint, announcing Thursday plans to spend $23 billion over five years to build six new factories, expand three existing ones and add a new research and development hub.The Swiss drugmaker said its expansion will allow it to manufacture all of the medicine intended for U.S. patients in the country, at a time when President Donald Trumps tariff policies have thrown global trading plans into turmoil. Novartis follows Eli Lilly, Merck & Co. and Johnson & Johnson in rolling out new capital expenditure initiatives as Trump pressures major corporations to bring manufacturing to the U.S.Novartis plan appears to reverse some of the companys recent pullback in the U.S., including closure of an R&D hub in San Diego the announced site of the new U.S. R&D site and shutdown of sites in North Carolina, Colorado, and Illinois. The company has disclosed closure of seven manufacturing sites between 2021 and 2024.Dive Insight:Novartis expansion will substantially boost its capital spending, which has run around $1 billion the past several years. It will also broaden Novartis commercial footprint, adding six new facilities to the 12 it already has. In the U.S., it currently lists its subsidiary headquarters in New Jersey, an R&D hub in Cambridge, Massachusetts, and plants in Indianapolis and New Jersey.Novartis said it will build two new plants to manufacture radiopharmaceuticals like its cancer drugs Pluvicto and Lutathera in Florida and in Texas, as well as expand existing plants in Indianapolis, Millburn, New Jersey, and Carlsbad, California.The sites for four facilities havent been determined yet. Three will make biologic drug substances, products, devices and packages, while the fourth will make chemical drug substances, pills and packaging.Already, Novartis relies on U.S. sites to make some of its most complex medicines, such as cell and gene therapies. With the new investment, it will locate some of its antisense oligonucleotide drug manufacturing in the U.S. for the first time.Novartis will also establish a $1.1 billion biomedical research innovation hub in San Diego. That site is due to open between 2028 and 2029.These investments will enable us to fully bring our supply chain and key technology platforms into the U.S. to support our strong U.S. growth outlook, said CEO Vas Narasimhan, in a statement.He also said the company is well-positioned to adjust to trade disruptions, stating that executives are fully confident in our 2025 guidance, mid- to long-term sales growth outlook and 2027 core margin guidance of 40%+.“Novartis is scheduled to release first quarter 2025 results on April 29. '

Oligonucleotide

07 Apr 2025

·www.prnewswire.com

DOSIsoft PLANET® Onco Dose receives CE MDR Mark and new FDA 510(k) clearance

PARIS, April 7, 2025 /PRNewswire/ -- DOSIsoft, leading provider of patient-specific imaging and dosimetry software solutions for radiation oncology and nuclear medicine, proudly announces the latest release of PLANET® Onco Dose version 3.2 – multi-radionuclide, personalized, voxel-based dosimetry platform for SIRT and MRT – now approved for market in EU under CE MDR Mark and in the US with FDA 510(k) clearance. End-to-end, versatile, vendor-neutral, the novel PLANET® release is specially designed to integrate multi-radionuclide, implement multi-workflow and support multi-therapy. This advanced software version allows clinics to cover a broader range of therapies by supporting voxel-based dose computation for 90Y, ¹⁷⁷Lu ¹⁶⁶Ho and ¹³¹I isotopes with the flexibility to incorporate new beta/gamma emitters. Clinicians can benefit from optimized multi-time point and newly introduced single-time point dosimetry workflows – reducing workload, enhancing patient comfort, streamlining clinical processes while ensuring accuracy. Validated against thorough Monte-Carlo simulations, it offers clinical-ready GPU-accelerated performances. "All-in-one dosimetry solution for Patient specific Theranostics," PLANET® enables highly personalized treatments including 177Lu-PSMA, 177Lu-PRRT, 90Y or 166Ho radioembolization, ¹³¹I therapies, and more. PLANET® Onco Dose is CE Marked under new EU MDR Regulation 2017/745 since February 17th, 2025. Learn more. PLANET® Onco Dose is US FDA 510(k) cleared since March 14th, 2025, expanding previous market clearance to version 3.2 rich feature set. As per FDA general rule for Radiopharmaceutical Therapy (RPT), voxel-based dosimetry solutions are intended specifically for absorbed dose calculation and should only be used with approved radioactive products. Learn more. "It is a milestone achievement and a collective work to provide all answers to the EU notified body and US FDA, Through our reinforced internal Quality System and commitment to the highest standards of safety, performance and compliance, DOSIsoft positions PLANET® Onco Dose, ahead of completion," highlights Marc Uszynski, CEO at DOSIsoft. "We are looking forward to seeing patients worldwide benefit from this safe and effective device in routine clinical use." About DOSIsoft Founded in 2002, DOSIsoft stands as market leader specialized in dosimetry software in Radiation Oncology and Nuclear Medicine to improve cancer patient safety and treatment quality. DOSIsoft provides the most competitive patient-specific quality assurance and medical imaging solutions in over 600 hospital centers in 60 countries. Spin-off between Gustave Roussy and Curie Institute in France, DOSIsoft constantly innovates in partnership with leading cancer institutes and research centers in the world, like recently through the Thera4Care European project. . Logo: Contact: Mme Xiaolu Chen Service Marketing [email protected] SOURCE DOSIsoft WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Radiation Therapy

03 Apr 2025

·endpts.com

SHL Medical opens $220M autoinjector site; DHL acquires clinical trial firm

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Swiss CDMO SHL Medical has opened a new $220 million factory in North Charleston, SC, which will manufacture autoinjectors for GLP-1 therapies, among other drugs, the company said Tuesday. The 360,000-square-foot factory will create 300 new jobs. Logistics provider DHL has acquired the clinical trial logistics firm Cryopdp from its parent company Cryoport, which specializes in supply chain logistics, for an undisclosed amount, according to a Monday press release. AGC Biologics has formed a new cell and gene technologies division, which will operate out of its sites in Milan, Italy ; Longmont, CO and its new Yokohama, Japan factory which will be operational in July. The division will be headed up by Luca Alberici, who previously served as general manager of the Milan factory, the company said Wednesday. Boehringer Ingelheim subsidiary NBE Therapeutics opened a new antibody-drug conjugate R&D facility in Basel, Switzerland, the company said Thursday. German biotech Siemens is partnering with Miko Pharma to develop manufacturing facilities in Ghana, according to a Tuesday press release. Siemens will build the new infrastructure for Miko’s operations in Ghana and will add 130 new jobs. Cellares has been granted an FDA Advanced Manufacturing Technology (AMT) designation for its automated cell therapy manufacturing tech, the company said Tuesday. The ATM is a program launched by the FDA in December 2023, with the aim of encouraging companies to use technologies to improve drug manufacturing. Sumitomo Chemical has launched a new CRO called Sumitomo Chemical Advanced Medical Solutions America, headquartered in Marlborough, MA, the company said Tuesday. The new CRO will provide services to Sumitomo Chemical’s Oligonucleotide CDMO. ASP Isotopes has started commercial manufacturing of the radioisotope Ytterbium-176 at its site in Pretoria, South Africa, the company said Tuesday. Ytterbium-176 is used in the production of the isotope Lutetium-177, which is used in drugs like Novartis’ Pluvicto. Bend Bioscience has added commercial dry spraying and dry granulation services at its 120,000-square-foot facility in Gainesville, GA, the company said Wednesday. Lonza’s new business structure launched on Tuesday, according to a press release. The company had initially announced the new structure in December 2024. Sterile injectable CDMO INCOG BioPharma Services said it plans to expand its Fishers, IN-based facilities this year, the company said Friday. The expansions will also bring the total number of INCOG employees to more than 350 by the end of the summer. DNA manufacturer 4basebio has received a Good Manufacturing Practice certification from the UK regulatory agency MHRA for its facility in Cambridge, UK, the company said Wednesday. Viva Biotech’s subsidiary Zhejiang Langhua Pharmaceutical has passed an on-site FDA inspection, the company said Friday.

INDClinical Study

100 Deals associated with Lutetium (177 Lu) Vipivotide Tetraxetan

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic castration-resistant prostate cancer	Canada	Advanced Accelerator Applications USA, Inc.	25 Aug 2022
PSMA-Positive Castration-Resistant Prostatic Cancer	United States	Novartis Pharmaceuticals Corp.	23 Mar 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Prostate Carcinoma	Phase 3	France	Novartis AG	12 Sep 2024
Oligometastatic Prostate Carcinoma	Phase 3	United States	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	China	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Japan	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Argentina	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Australia	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Austria	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Belgium	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Brazil	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Canada	Novartis Pharmaceuticals Corp.	12 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2025	Not Applicable	Prostatic Cancer	117	177Lutetium-PSMA-617 (Luminal A-like (LumA))	zckaiseueu(xeljoytlwv) = qkkmdxhgoc wrtiehzipd (pufecorlnc )	Positive	28 Apr 2025
				177Lutetium-PSMA-617 (Luminal B-like (LumB))	zckaiseueu(xeljoytlwv) = bevdsqitou wrtiehzipd (pufecorlnc )
ASCO_GU2025 Manual	Not Applicable	Metastatic castration-resistant prostate cancer	643	177Lu-PSMA-617	pmztbppzdm(otinirrvhd) = epfgcunnru ifhtmhhebv (hrlbrfpdjp, 14.6 - 16.3) View more	Negative	13 Feb 2025
NCT03511664 (VISION, ASCO_GU2025) Manual	Phase 3	Metastatic castration-resistant prostate cancer	551	177Lu-PSMA-617 + ARPIs	gztkmykjsu(fhfqbbegnc) = upqfxplinr wcvsbiwccw (hklhvdwkjx )	Positive	13 Feb 2025
				177Lu-PSMA-617	gztkmykjsu(fhfqbbegnc) = mdwtzojvxl wcvsbiwccw (hklhvdwkjx )
ASCO_GU2025 Manual	Not Applicable	Metastatic Prostate Carcinoma EPCAM \| DLL3 \| CHGA ... View more	24	177Lu-PSMA-617	bqtbhrfdbm(nmbyfbedzo) = jkizyinzuk kpzzmngdnb (plxmdpmotz )	Positive	13 Feb 2025
				177Lu-PSMA-617 (AR-V7-positive)	gamfwvnqjl(mgygithcak) = akiwkpomvs qqbtlurmrv (zkftizevxd )
ASCO_GU2025	Not Applicable	Metastatic castration-resistant prostate cancer	100	lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT) (Bone only)	eadmymnayp(vllsppemue) = mexoofuchk iplesxmsts (zsgtudpmzm, 43 - 70) View more	Positive	13 Feb 2025
				lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT) (Lung-involved)	eadmymnayp(vllsppemue) = wtcahhojdz iplesxmsts (zsgtudpmzm, 27 - 79) View more
ASCO_GU2025	Not Applicable	Metastatic castration-resistant prostate cancer prostate-specific membrane antigen (PSMA)	72	lutetium-177-PSMA-617 (In-field progression (IFP))	whvfexdupx(uutqyivawi) = flctsyhqqa lclyjyfcta (hablwcubqu, 6.2 - 12.8) View more	Positive	13 Feb 2025
PRECISION (ASCO_GU2025)	Not Applicable	Metastatic castration-resistant prostate cancer prostate-specific antigen	152	Abiraterone	yqggrsbgut(sztxrzbhwa) = kqebprwfmq egyexurlyr (lfoumgpdhf ) View more	Positive	13 Feb 2025
				Enzalutamide	yqggrsbgut(sztxrzbhwa) = otbiiwtxkn egyexurlyr (lfoumgpdhf ) View more
PRECISION (ASCO_GU2025)	Not Applicable	Metastatic castration-resistant prostate cancer prostate-specific antigen	431	177Lu-PSMA-617taxane (Prompt cohort (1 ARPI and 1 taxane))	repgvrozzn(wovavvddsn) = mfmsxdknpc yfdyvrihbm (duvrpokbor ) View more	Positive	13 Feb 2025
				177Lu-PSMA-617 (Deferred cohort (>1 ARPI and/or >1 taxane))	repgvrozzn(wovavvddsn) = goegbyzgld yfdyvrihbm (duvrpokbor ) View more
VISION trial (ASCO_GU2025)	Not Applicable	Metastatic castration-resistant prostate cancer PSMA PET+	84	177Lu-PSMA-617 (Caucasian patients)	stqhkomwjb(igxmedafrv) = qsxtrqazkc gualibfenv (iuvxzkqhfd ) View more	Positive	13 Feb 2025
				177Lu-PSMA-617 (Black patients)	stqhkomwjb(igxmedafrv) = dowkdczimu gualibfenv (iuvxzkqhfd ) View more
ASCO_GU2025	Not Applicable	Metastatic castration-resistant prostate cancer	256	177Lu-PSMA-617 with ARPI	omkyjrimre(lukcumopmq) = itflocriav smomhbnlbj (veqdtrevda, NE - NE)	-	13 Feb 2025
				177Lu-PSMA-617 alone	omkyjrimre(lukcumopmq) = nlaahnkomj smomhbnlbj (veqdtrevda, 11.6 - 19.1)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis